927 related articles for article (PubMed ID: 16689923)
1. Protein-misfolding diseases and chaperone-based therapeutic approaches.
Chaudhuri TK; Paul S
FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
[TBL] [Abstract][Full Text] [Related]
2. Protein misfolding in neurodegenerative diseases.
Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
[TBL] [Abstract][Full Text] [Related]
3. Modulation of neurodegeneration by molecular chaperones.
Muchowski PJ; Wacker JL
Nat Rev Neurosci; 2005 Jan; 6(1):11-22. PubMed ID: 15611723
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the mysteries of protein folding and misfolding.
Ecroyd H; Carver JA
IUBMB Life; 2008 Dec; 60(12):769-74. PubMed ID: 18767168
[TBL] [Abstract][Full Text] [Related]
5. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
Aigelsreiter A; Janig E; Stumptner C; Fuchsbichler A; Zatloukal K; Denk H
Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of disease II: cellular protein quality control.
Outeiro TF; Tetzlaff J
Semin Pediatr Neurol; 2007 Mar; 14(1):15-25. PubMed ID: 17331880
[TBL] [Abstract][Full Text] [Related]
7. Proteopathy: the next therapeutic frontier?
Walker LC; LeVine H
Curr Opin Investig Drugs; 2002 May; 3(5):782-7. PubMed ID: 12090553
[TBL] [Abstract][Full Text] [Related]
8. The role of molecular chaperones in human misfolding diseases.
Broadley SA; Hartl FU
FEBS Lett; 2009 Aug; 583(16):2647-53. PubMed ID: 19393652
[TBL] [Abstract][Full Text] [Related]
9. Developing therapeutics for the diseases of protein misfolding.
May BC; Govaerts C; Cohen FE
Neurology; 2006 Jan; 66(2 Suppl 1):S118-22. PubMed ID: 16432139
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches to protein-misfolding diseases.
Cohen FE; Kelly JW
Nature; 2003 Dec; 426(6968):905-9. PubMed ID: 14685252
[TBL] [Abstract][Full Text] [Related]
11. [Neurodegenerative conformational disease and its molecular bases].
Li WW; Cai DF; Ren HM
Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
[TBL] [Abstract][Full Text] [Related]
12. Structure and function of the molecular chaperone Hsp104 from yeast.
Grimminger-Marquardt V; Lashuel HA
Biopolymers; 2010 Mar; 93(3):252-76. PubMed ID: 19768774
[TBL] [Abstract][Full Text] [Related]
13. Approaches to the isolation and characterization of molecular chaperones.
Nicoll WS; Boshoff A; Ludewig MH; Hennessy F; Jung M; Blatch GL
Protein Expr Purif; 2006 Mar; 46(1):1-15. PubMed ID: 16199180
[TBL] [Abstract][Full Text] [Related]
14. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.
Glabe CG
Neurobiol Aging; 2006 Apr; 27(4):570-5. PubMed ID: 16481071
[TBL] [Abstract][Full Text] [Related]
15. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?
Carver JA; Rekas A; Thorn DC; Wilson MR
IUBMB Life; 2003 Dec; 55(12):661-8. PubMed ID: 14769002
[TBL] [Abstract][Full Text] [Related]
16. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
Naeem A; Fazili NA
Cell Biochem Biophys; 2011 Nov; 61(2):237-50. PubMed ID: 21573992
[TBL] [Abstract][Full Text] [Related]
17. Amino acid sequence determinants and molecular chaperones in amyloid fibril formation.
Nerelius C; Fitzen M; Johansson J
Biochem Biophys Res Commun; 2010 May; 396(1):2-6. PubMed ID: 20494101
[TBL] [Abstract][Full Text] [Related]
18. Modeling and analysis of prion dynamics in the presence of a chaperone.
Kumar R; Murali P
Math Biosci; 2008 May; 213(1):50-5. PubMed ID: 18362035
[TBL] [Abstract][Full Text] [Related]
19. Contribution of glutamatergic signaling to nitrosative stress-induced protein misfolding in normal brain aging and neurodegenerative diseases.
Nakamura T; Gu Z; Lipton SA
Aging Cell; 2007 Jun; 6(3):351-9. PubMed ID: 17388798
[TBL] [Abstract][Full Text] [Related]
20. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding.
Nakamura T; Lipton SA
Cell Death Differ; 2007 Jul; 14(7):1305-14. PubMed ID: 17431424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
